Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • Tuesday
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to BuyZacks Investment Research • 09/08/23
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)Zacks Investment Research • 08/31/23
Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/29/23
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business UpdatesGlobeNewsWire • 08/10/23
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's DiseaseGlobeNewsWire • 07/17/23
Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023GlobeNewsWire • 07/06/23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business OfficerGlobeNewsWire • 05/22/23
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual MeetingGlobeNewsWire • 04/25/23
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual MeetingGlobeNewsWire • 04/11/23
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/28/23
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International ConferenceGlobeNewsWire • 03/28/23
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business UpdatesGlobeNewsWire • 03/23/23
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific ConferencesGlobeNewsWire • 03/06/23
Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET PathwayGlobeNewsWire • 02/01/23
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific OfficerGlobeNewsWire • 01/31/23
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in NeurotherapeuticsGlobeNewsWire • 12/21/22
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MNDGlobeNewsWire • 12/05/22
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD ConferenceGlobeNewsWire • 11/29/22
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MNDGlobeNewsWire • 11/28/22
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire • 11/21/22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate UpdatesGlobeNewsWire • 11/10/22